Vicore Pharma (VCRE)
Develops oral AT2 receptor agonists for idiopathic pulmonary fibrosis.
$11.26
At close+0.19 (+1.71%)
Something off on this page? Send us feedback.
EPSReportedEstimate
—Nov '24Feb '25May '25Nov '25Feb '26May '26Aug '26
Reported—−$0.05−$0.05—−$0.05−$0.06−$0.04−$0.05
Estimate——−$0.03−$0.04−$0.05−$0.05−$0.05−$0.04
Surprise——−42.9%—−3.1%−18.7%+18.8%−24.4%
RevenueReportedEstimate
—Nov '24Feb '25May '25Nov '25Feb '26May '26Aug '26
Reported——$459.0K$89.3K$84.7K$43.3K$63.2K$225.9K
Estimate———$74.4K—$86.6K$50.2K$108.0K
Surprise———+20.0%—−50.0%+26.0%+109.3%
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.04 | −$0.05 | −24.4% |
| May 2026 | −$0.05 | −$0.04 | +18.8% |
| Feb 2026 | −$0.05 | −$0.06 | −18.7% |
| Nov 2025 | −$0.05 | −$0.05 | −3.1% |
The latest year is open to everyone — the 3 quarters behind it read with an account. Sign in | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | −$0.04 | −$0.05 | −24.4% | $108.0K | $225.9K | +109.3% | −8.0% |
| May 6, 2026 | −$0.05 | −$0.04 | +18.8% | $50.2K | $63.2K | +26.0% | — |
| Feb 27, 2026 | −$0.05 | −$0.06 | −18.7% | $86.6K | $43.3K | −50.0% | — |
| Nov 5, 2025 | −$0.05 | −$0.05 | −3.1% | — | $84.7K | — | — |
The latest year is open to everyone — the 3 quarters behind it read with an account. Sign in | |||||||
| May 6, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 5, 2024 | |||||||